Therapeutics News and Research

RSS

Scientists uncover role of cancer stem cell marker: controlling gene expression

Scientists at Jefferson's Kimmel Cancer Center in Philadelphia have made an extraordinary advance in the understanding of the function of a gene previously shown to be part of an 11-gene "signature" that can predict which tumors will be aggressive and likely to spread.

18 Jan 2008

New genetic variations associated with lipid levels, risk for coronary artery disease

Environmental and genetic factors influence a person's blood fat, or lipid levels, important risk factors for coronary artery disease (CAD). While there is some understanding of the environmental contribution, the role of genetics has been less defined.

14 Jan 2008

Genomic screen identifies 273 human proteins required for HIV propagation

In some ways, HIV resembles a minimalist painter, using a few basic components to achieve dramatic effects.

11 Jan 2008

New study highlights importance soluble proteins, called cytokines, in Alzheimer's

An extraordinary new scientific study, which for the first time documents marked improvement in Alzheimer's disease within minutes of administration of a therapeutic molecule, has just been published in the Journal of Neuroinflammation .

10 Jan 2008

Morphotek announces agreement for development of antibodies to treat prostate cancer

Morphotek, Inc., a subsidiary of Eisai Co., Ltd., has announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of therapeutic antibodies to a cancer-associated protein identified by NCI researchers.

10 Jan 2008

Experts say Dengue fever threatens to spread across the U.S

Health officials in the U.S. say the tropical infection Dengue fever is in danger of spreading across the country.

10 Jan 2008

Trius Therapeutics starts U.S. phase I trial for Oxazolidinone antibacterial drug

Trius Therapeutics, Inc. has announced that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains.

9 Jan 2008

Researchers trigger insulin production in diabetic mice

If the human body were a stage, then proteins would rank among the lead actors in the play we call "Life."

9 Jan 2008

Dengue seen as potential threat to US public health

A disease most Americans have never heard of could soon become more prevalent if dengue, a flu-like illness that can turn deadly, continues to expand into temperate climates and increase in severity, according to a new commentary by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and David M. Morens, M.D., Fauci's senior scientific advisor.

9 Jan 2008

Nastech receives U.S. patent for methods for identifying cell-specific targeting peptides

Nastech Pharmaceutical Company Inc. has announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 10/976,942, entitled "Phage Displayed Trp Cage Ligands".

9 Jan 2008

A look at China's most innovative health biotechnology companies

Government funds innovation but venture capital needed; Wary investors 'need to be shown the exits'; Returning 'sea turtles' bring expertise, international credibility

8 Jan 2008

Baxter to develop recombinant Factor IX proteins to treat hemophilia B

Baxter International Inc. has announced that it has initiated pre-clinical programs to develop recombinant Factor IX proteins to treat hemophilia B.

From Baxter International Inc. 7 Jan 2008

Growing artificial skin from patients' own cells

There is new hope for patients with chronic wounds: euroderm GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig have been granted approval to produce artificial skin from patients’ own cells.

7 Jan 2008

Genmab announces HuMax-CD32b pre-clinical program

Genmab A/S has announced a new pre-clinical antibody program called HuMax-CD32b. This fully human IgG1,k antibody targets the CD32b receptor found on immune cells and hematological tumors.

7 Jan 2008

Need for greater recognition of the use of placebos

In the first study examining American physicians' use of placebos in clinical practice in the 21st Century, 45 percent of Chicago internists report they have used a placebo at some time during their clinical practice researchers report in the January issue of Journal of General Internal Medicine.

4 Jan 2008